Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

BACKGROUND: Data on the use of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation are limited. The current study aimed to assess the efficacy of ICIs in EGFR-mutant advanced NSCLC and explore the relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Tian, Yu, Min, Li, Juan, Jiang, Maoqiong, Ma, Daiyuan, Tang, Shubin, Lin, Zhiyu, Chen, Lin, Gong, Youling, Zhu, Jiang, Zhou, Qiang, Huang, Meijuan, Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648573/
https://www.ncbi.nlm.nih.gov/pubmed/34888234
http://dx.doi.org/10.3389/fonc.2021.739090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648573/
https://www.ncbi.nlm.nih.gov/pubmed/34888234
http://dx.doi.org/10.3389/fonc.2021.739090

Ejemplares similares